Free Trial
NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Kazia Therapeutics logo
$0.95 -0.04 (-4.07%)
Closing price 03/27/2025 03:50 PM Eastern
Extended Trading
$0.95 0.00 (-0.21%)
As of 03/27/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Key Stats

Today's Range
$0.93
$0.97
50-Day Range
$0.76
$1.90
52-Week Range
$0.76
$15.80
Volume
22,800 shs
Average Volume
852,640 shs
Market Capitalization
$4.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Remove Ads

Kazia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

KZIA MarketRank™: 

Kazia Therapeutics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kazia Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kazia Therapeutics' stock forecast and price target.
    • Percentage of Shares Shorted

      2.32% of the float of Kazia Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Kazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Kazia Therapeutics has recently increased by 94.46%, indicating that investor sentiment is decreasing significantly.
    • Dividend Yield

      Kazia Therapeutics does not currently pay a dividend.

    • Dividend Growth

      Kazia Therapeutics does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      2.32% of the float of Kazia Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Kazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Kazia Therapeutics has recently increased by 94.46%, indicating that investor sentiment is decreasing significantly.
    • News Sentiment

      Kazia Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
    • News Coverage This Week

      MarketBeat has tracked 2 news articles for Kazia Therapeutics this week, compared to 0 articles on an average week.
    • Search Interest

      Only 1 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
    • MarketBeat Follows

      3 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 1.00% of the stock of Kazia Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

    • Read more about Kazia Therapeutics' insider trading history.
    Receive KZIA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    KZIA Stock News Headlines

    Kazia Therapeutics announces research grant awarded from MJFF
    Elon Warns: Exec Order 14024 Targets Dollar
    Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
    Kazia Therapeutics initiated with a Buy at Maxim
    Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
    See More Headlines

    KZIA Stock Analysis - Frequently Asked Questions

    Kazia Therapeutics' stock was trading at $1.77 at the start of the year. Since then, KZIA shares have decreased by 46.3% and is now trading at $0.95.
    View the best growth stocks for 2025 here
    .

    Kazia Therapeutics's stock reverse split on Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Kazia Therapeutics' top institutional shareholders include Barclays PLC (2.38%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Bryce Carmine, James Garner and Steven Coffey.
    View institutional ownership trends
    .

    Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

    Company Calendar

    Today
    3/27/2025
    Fiscal Year End
    6/30/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:KZIA
    Previous Symbol
    ASX:KZA
    Employees
    12
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $11.50
    High Stock Price Target
    $20.00
    Low Stock Price Target
    $3.00
    Potential Upside/Downside
    +1,110.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $2.31 million
    Price / Cash Flow
    N/A
    Book Value
    ($1.97) per share
    Price / Book
    -0.48

    Miscellaneous

    Free Float
    4,986,000
    Market Cap
    $4.78 million
    Optionable
    Optionable
    Beta
    2.28
    The 10 Best AI Stocks to Own in 2025 Cover

    Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

    Get This Free Report

    This page (NASDAQ:KZIA) was last updated on 3/28/2025 by MarketBeat.com Staff
    From Our Partners